GSK-1521498 | CAS#1007573-18-3 | μ-Opioid receptor antagonist

MedKoo Cat#: 525206 | Name: GSK-1521498

Description:

WARNING: This product is for research use only, not for human or veterinary use.

GSK-1521498 is a novel μ-Opioid receptor antagonist. It has been shown to attenuate reward-driven compulsive behaviours, such as stimulant drug seeking or binge eating, in animals and humans.

Chemical Structure

GSK-1521498

CAS#1007573-18-3 (free base)

Theoretical Analysis

MedKoo Cat#: 525206

Name: GSK-1521498

CAS#: 1007573-18-3 (free base)

Chemical Formula: C24H20F2N4

Exact Mass: 402.1656

Molecular Weight: 402.44

Elemental Analysis: C, 71.63; H, 5.01; F, 9.44; N, 13.92

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

1007573-18-3 (free base) 1007578-24-6 (HCl)

Synonym

GSK-1521498; GSK1521498; GSK 1521498; GSK-1521498B.

IUPAC/Chemical Name

N-((3,5-difluoro-3'-(1H-1,2,4-triazol-3-yl)-[1,1'-biphenyl]-4-yl)methyl)-2,3-dihydro-1H-inden-2-amine

InChi Key

WIEDUMBCZQRGSY-UHFFFAOYSA-N

InChi Code

InChI=1S/C24H20F2N4/c25-22-11-19(15-6-3-7-18(8-15)24-28-14-29-30-24)12-23(26)21(22)13-27-20-9-16-4-1-2-5-17(16)10-20/h1-8,11-12,14,20,27H,9-10,13H2,(H,28,29,30)

SMILES Code

FC1=C(CNC2CC3=C(C=CC=C3)C2)C(F)=CC(C4=CC=CC(C5=NNC=N5)=C4)=C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 402.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Ripley TL, Sanchez-Roige S, Bullmore ET, Mugnaini M, Maltby K, Miller SR, Wille DR, Nathan P, Stephens DN. The novel mu-opioid antagonist, GSK1521498, reduces ethanol consumption in C57BL/6J mice. Psychopharmacology (Berl). 2015 Sep;232(18):3431-41. doi: 10.1007/s00213-015-3995-x. Epub 2015 Jul 5. PubMed PMID: 26141191; PubMed Central PMCID: PMC4537503. 2: Kelly E, Mundell SJ, Sava A, Roth AL, Felici A, Maltby K, Nathan PJ, Bullmore ET, Henderson G. The opioid receptor pharmacology of GSK1521498 compared to other ligands with differential effects on compulsive reward-related behaviours. Psychopharmacology (Berl). 2015 Jan;232(1):305-14. doi: 10.1007/s00213-014-3666-3. Epub 2014 Jun 29. PubMed PMID: 24973897; PubMed Central PMCID: PMC4281354. 3: Ziauddeen H, Subramaniam N, Cambridge VC, Medic N, Farooqi IS, Fletcher PC. Studying food reward and motivation in humans. J Vis Exp. 2014 Mar 19;(85). doi: 10.3791/51281. PubMed PMID: 24686284; PubMed Central PMCID: PMC4153444. 4: Ziauddeen H, Nathan PJ, Dodds C, Maltby K, Miller SR, Waterworth D, Song K, Warren L, Hosking L, Zucchetto M, Bush M, Johnson LV, Sarai B, Mogg K, Bradley BP, Richards DB, Fletcher PC, Bullmore ET. The effects of alcohol on the pharmacokinetics and pharmacodynamics of the selective mu-opioid receptor antagonist GSK1521498 in healthy subjects. J Clin Pharmacol. 2013 Oct;53(10):1078-90. doi: 10.1002/jcph.110. Epub 2013 Aug 11. PubMed PMID: 23934621; PubMed Central PMCID: PMC4282435. 5: Giuliano C, Robbins TW, Wille DR, Bullmore ET, Everitt BJ. Attenuation of cocaine and heroin seeking by μ-opioid receptor antagonism. Psychopharmacology (Berl). 2013 May;227(1):137-47. doi: 10.1007/s00213-012-2949-9. Epub 2013 Jan 9. PubMed PMID: 23299095; PubMed Central PMCID: PMC3622002. 6: Cambridge VC, Ziauddeen H, Nathan PJ, Subramaniam N, Dodds C, Chamberlain SR, Koch A, Maltby K, Skeggs AL, Napolitano A, Farooqi IS, Bullmore ET, Fletcher PC. Neural and behavioral effects of a novel mu opioid receptor antagonist in binge-eating obese people. Biol Psychiatry. 2013 May 1;73(9):887-94. doi: 10.1016/j.biopsych.2012.10.022. Epub 2012 Dec 14. PubMed PMID: 23245760; PubMed Central PMCID: PMC3898083. 7: Ziauddeen H, Chamberlain SR, Nathan PJ, Koch A, Maltby K, Bush M, Tao WX, Napolitano A, Skeggs AL, Brooke AC, Cheke L, Clayton NS, Sadaf Farooqi I, O'Rahilly S, Waterworth D, Song K, Hosking L, Richards DB, Fletcher PC, Bullmore ET. Effects of the mu-opioid receptor antagonist GSK1521498 on hedonic and consummatory eating behaviour: a proof of mechanism study in binge-eating obese subjects. Mol Psychiatry. 2013 Dec;18(12):1287-93. doi: 10.1038/mp.2012.154. Epub 2012 Nov 13. Erratum in: Mol Psychiatry. 2014 Dec;19(12):1341. PubMed PMID: 23147384; PubMed Central PMCID: PMC3835938. 8: Giuliano C, Robbins TW, Nathan PJ, Bullmore ET, Everitt BJ. Inhibition of opioid transmission at the μ-opioid receptor prevents both food seeking and binge-like eating. Neuropsychopharmacology. 2012 Nov;37(12):2643-52. doi: 10.1038/npp.2012.128. Epub 2012 Jul 18. PubMed PMID: 22805601; PubMed Central PMCID: PMC3473330. 9: Chamberlain SR, Mogg K, Bradley BP, Koch A, Dodds CM, Tao WX, Maltby K, Sarai B, Napolitano A, Richards DB, Bullmore ET, Nathan PJ. Effects of mu opioid receptor antagonism on cognition in obese binge-eating individuals. Psychopharmacology (Berl). 2012 Dec;224(4):501-9. doi: 10.1007/s00213-012-2778-x. Epub 2012 Jul 3. PubMed PMID: 22752384. 10: Nathan PJ, Bush MA, Tao WX, Koch A, Davies KM, Maltby K, O'Neill BV, Napolitano A, Skeggs AL, Brooke AC, Richards DB, Williams PM, Bullmore ET. Multiple-dose safety, pharmacokinetics, and pharmacodynamics of the μ-opioid receptor inverse agonist GSK1521498. J Clin Pharmacol. 2012 Oct;52(10):1456-67. Epub 2011 Dec 12. PubMed PMID: 22162534. 11: Ignar DM, Goetz AS, Noble KN, Carballo LH, Stroup AE, Fisher JC, Boucheron JA, Brainard TA, Larkin AL, Epperly AH, Shearer TW, Sorensen SD, Speake JD, Hommel JD. Regulation of ingestive behaviors in the rat by GSK1521498, a novel micro-opioid receptor-selective inverse agonist. J Pharmacol Exp Ther. 2011 Oct;339(1):24-34. doi: 10.1124/jpet.111.180943. Epub 2011 Jun 28. PubMed PMID: 21712426. 12: Nathan PJ, O'Neill BV, Bush MA, Koch A, Tao WX, Maltby K, Napolitano A, Brooke AC, Skeggs AL, Herman CS, Larkin AL, Ignar DM, Richards DB, Williams PM, Bullmore ET. Opioid receptor modulation of hedonic taste preference and food intake: a single-dose safety, pharmacokinetic, and pharmacodynamic investigation with GSK1521498, a novel μ-opioid receptor inverse agonist. J Clin Pharmacol. 2012 Apr;52(4):464-74. doi: 10.1177/0091270011399577. Epub 2011 May 24. PubMed PMID: 21610207. 13: Rabiner EA, Beaver J, Makwana A, Searle G, Long C, Nathan PJ, Newbould RD, Howard J, Miller SR, Bush MA, Hill S, Reiley R, Passchier J, Gunn RN, Matthews PM, Bullmore ET. Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans. Mol Psychiatry. 2011 Aug;16(8):826-35, 785. doi: 10.1038/mp.2011.29. Epub 2011 Apr 19. PubMed PMID: 21502953; PubMed Central PMCID: PMC3142667.